Skip to content
Menu

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $91

Benzinga Newsdesk 6 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $88 to $91.

Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $88 to $91.

Read at benzinga.com